Effects of the novel antiarrhythmic agent azimilide on experimental atrial fibrillation and atrial electrophysiologic properties

Cardiovascular Research
S NattelD St-Georges

Abstract

This study was designed to evaluate how the atrial electrophysiological and antiarrhythmic effects of azimilide compare with those of the specific rapid delayed rectifier (IKr) blocker dofetilide. Azimilide, a new class III drug, was initially believed to be a highly selective blocker of the slow delayed rectifier (IKs), but recent studies suggest that azimilide potently blocks IKr. Thus, it has been suggested that azimilide's in vivo effects may simply be due to IKr blockade. Dose regimens producing stable effects over time were developed, and two dose levels of azimilide (10 and then 20 mg/kg) or dofetilide (0.08 and then 0.16 mg/kg) were administered to morphine/chloralose-anesthetized dogs during sustained vagal atrial fibrillation (AF). Epicardial mapping was used to measure conduction velocity and AF cycle length. Azimilide terminated AF in 13/14 dogs (93%), while dofetilide terminated AF in 6/12 (50%, P < 0.05). While dofetilide had strong reverse use-dependent effects on atrial ERP (e.g. at lower doses, dofetilide increased ERP by 51 +/- 3% at a basic cycle length, BCL, of 400 ms and by 17 +/- 3% at a BCL of 200 ms), azimilide's effects on ERP were rate-independent (ERP increased at lower dose by 38 +/- 6%, BCL 400 ms; ...Continue Reading

Citations

Sep 7, 2001·Biochemical Pharmacology·R R BrooksD J Triggle
Dec 2, 2009·Nature Reviews. Drug Discovery·Heike WulffLuis A Pardo
Jun 9, 2000·Annual Review of Physiology·S NattelL Yue
May 10, 2002·Circulation Journal : Official Journal of the Japanese Circulation Society·Hidehiko NagasawaHiroshi Inoue
Jul 1, 2004·Circulation Journal : Official Journal of the Japanese Circulation Society·Junichiro MiakeIchiro Hisatome
Mar 25, 1999·Journal of Cardiovascular Electrophysiology·S Nattel
Jun 19, 2001·Current Cardiology Reports·B N Singh, J S Sarma
Feb 22, 2011·Pharmacology & Therapeutics·A J WorkmanA C Rankin
Dec 20, 2005·Pacing and Clinical Electrophysiology : PACE·Hirotaka SugiuraYoshifusa Aizawa
Sep 3, 2003·Journal of Cardiovascular Electrophysiology·Maurits C E F Wijffels, Harry J G M Crijns
Nov 24, 1999·The American Journal of Cardiology·S Nattel, B N Singh
Sep 12, 2007·Expert Opinion on Therapeutic Targets·Deepak Bhakta, John M Miller
Jun 24, 2004·Expert Opinion on Investigational Drugs·Anirban Choudhury, Gregory Y H Lip
Nov 4, 2000·Expert Opinion on Investigational Drugs·R Abrol, R L Page
Oct 31, 2000·American Heart Journal·R H Falk, J M Decara
Mar 20, 2004·Expert Review of Cardiovascular Therapy·Bente BrendorpChristian Torp-Pedersen
Dec 20, 2002·Journal of Cardiovascular Pharmacology and Therapeutics·Fuhua ChenThomas S Klitzner
Jul 14, 2001·Journal of Cardiovascular Pharmacology and Therapeutics·S C VerduynM A Vos
Sep 21, 2004·Journal of Cardiovascular Pharmacology and Therapeutics·Bramah N Singh, Nitin Wadhani
Mar 24, 2000·Drugs·D Clemett, A Markham
Sep 21, 2002·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Bente BrendorpLars Køber
Jul 13, 2000·Journal of Cardiovascular Pharmacology·V V FedorovL V Rosenshtraukh
Oct 17, 2001·Journal of Cardiovascular Pharmacology·O F SharifovL V Rosenshtraukh
Dec 22, 1999·Journal of Cardiovascular Pharmacology·X Q QiP Dorian
Apr 30, 2003·Journal of Cardiovascular Pharmacology·Akiko Shiroshita-TakeshitaSatoshi Ogawa
Feb 10, 2000·Current Opinion in Cardiology·P T Sager
Feb 5, 1999·Current Opinion in Cardiology·P T Sager
Aug 15, 2000·Journal of Cardiovascular Pharmacology·V Nand, S A Doggrell

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Atrial Filbrillation

Atrial fibrillation refers to the abnormal heart rhythm characterized by rapid and irregular beating of the atria. Here is the latest research.

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Cardiac Conduction System

The cardiac conduction system is a specialized tract of myocardial cells responsible for maintaining normal cardiac rhythm. Discover the latest research on the cardiac conduction system here.

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.